Eli Lilly (LLY)
722.57
+3.18 (0.44%)
NYSE · Last Trade: May 29th, 6:32 PM EDT
Detailed Quote
Previous Close | 719.39 |
---|---|
Open | 719.23 |
Bid | 720.55 |
Ask | 721.75 |
Day's Range | 716.96 - 727.33 |
52 Week Range | 677.09 - 972.53 |
Volume | 2,785,539 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | 6.000 (0.83%) |
1 Month Average Volume | 5,091,992 |
Chart
About Eli Lilly (LLY)
Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
News & Press Releases

Eli Lilly is rapidly encroaching on Novo Nordisk's yearslong lead in GLP-1 drugs. Can Novo hold its tentpole position?
Via Investor's Business Daily · May 29, 2025

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels.
Via The Motley Fool · May 28, 2025
Eli Lilly stock down 19% in May, on track for worst month since 2009. But June historically brings better fortune, with 67% chance of closing higher.
Via Benzinga · May 27, 2025
Eli Lilly to acquire SiteOne Therapeutics in a deal worth up to $1 billion, advancing the development of a potential non-opioid treatment for chronic pain.
Via Benzinga · May 27, 2025
Via The Motley Fool · May 27, 2025
Adjusted net profit jumped 64.5% YoY to hit a record high of RMB10.7 billion during the quarter.
Via Stocktwits · May 27, 2025
President Trump has good news for Novo Nordisk investors, and more may be on the way.
Via The Motley Fool · May 27, 2025
The $1 billion is inclusive of an upfront payment and subsequent payments upon achievement of certain regulatory and commercial milestones.
Via Stocktwits · May 27, 2025
Via Benzinga · May 27, 2025
Via Benzinga · May 27, 2025
Via The Motley Fool · May 27, 2025
Via The Motley Fool · May 27, 2025
Via The Motley Fool · May 26, 2025
Great things are happening to the stocks in this article.
They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.
Via StockStory · May 26, 2025
Knowing what Congressional leaders are buying can give investors insight into future legislation that could benefit these companies
Via MarketBeat · May 23, 2025
Via The Motley Fool · May 23, 2025
Growth is oxygen.
But when it evaporates, the consequences can be extreme - ask anyone who bought Cisco in the Dot-Com Bubble (Nvidia?) or newer investors who lived through the 2020 to 2022 COVID cycle.
Via StockStory · May 23, 2025
Truist noted on Thursday that the $200/month price point is "highly attractive compared to other price points in the market," including Hims & Hers' compounded Semaglutide, Wegovy, and Liraglutide subscription programs.
Via Stocktwits · May 22, 2025